Core Insights - Carillon Eagle Small Cap Growth Fund reported marginal gains in small-cap stocks for Q4 2025, with the Russell 2000 Growth Index returning 13.01% and the Value Index at 12.58% [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending sectors heading into 2026 [1] Company Highlights: Establishment Labs Holdings Inc. (NASDAQ:ESTA) - Establishment Labs Holdings Inc. is recognized as a leading contributor to the fund, focusing on advanced breast implants and reconstructive plastic surgeries [2][3] - The stock closed at $74.60 on February 13, 2026, with an 8.35% return in the past month and a significant 102.73% increase over the past twelve months, giving it a market capitalization of $2.125 billion [2] - The company has seen robust demand following FDA approval in late 2024, with strong brand recognition and clinical advantages over competitors, positioning it for EBITDA profitability by late 2025 or early 2026 [3] - Establishment Labs is expected to achieve cash flow positivity in 2026, supported by a recent FDA application for its implant for primary and revision breast reconstruction [3] Market Position - Establishment Labs Holdings Inc. was held by 29 hedge fund portfolios at the end of Q3 2025, indicating a slight increase from 28 in the previous quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential with less downside risk [4]

The U.S. medical device market is filled with companies that have innovative technology, but my bullish outlook on Establishment Labs ( ESTA ) is not based solely upon the successful launch of the Motiva breast implantsI am an investor specializing in the consumer products sector with a focus on identifying companies that offer a unique combination of strong brand recognition, solid financials, and growth potential. I have a keen eye for consumer trends and an in-depth understanding of the industry, which h ...

The company reported adjusted earnings before interest and taxes of €580 million in the fourth quarter, shy of analyst expectations. ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund focuses on long-term, competitively positioned companies that are well-managed and have significant potential in untapped markets. The letter also addressed the advancements in AI and how humans define themselves in the changing landscape. In Q4, the fund generated a return of 0.19% (Institutional Shares), underperforming the Russell 2 ...

Company Overview - Establishment Labs is a medical technology company focused on breast aesthetics and reconstruction, emphasizing innovation to enhance women's health and well-being [2] - The company has been operational for 20 years, selling over 4.5 million devices across 90 countries [3] Recent Performance - Establishment Labs reported a 27% growth on a global basis for the year 2025, indicating strong market performance [3] - The company successfully launched its products in the U.S. after receiving FDA approval at the end of 2024, achieving a strong start in its first year [3] Future Outlook - Establishment Labs is well-positioned for significant growth in 2026 and beyond, with a focus on science-based innovation that sets a new standard in the breast aesthetics and reconstruction market [2][3]

Core Insights - The investment firm has demonstrated resilience in a challenging macroeconomic and geopolitical environment, achieving a 21% growth in assets under management (AuM) in 2025 [3] - The firm added $30.2 billion in total new assets, aligning with its guidance of $26 billion to $31 billion [3] - Fundraising reached $26 billion in 2025, marking the highest year for new client demand in the firm's 30-year history, representing a 22% increase from the previous year [3] - M&A activities contributed an additional $4 billion to the firm's growth [3] - Bespoke solutions accounted for 72% of inflows, with both mandates and evergreens achieving their strongest performance to date [3]

Summary of Establishment Labs FY Conference Call Company Overview - **Company**: Establishment Labs (NasdaqCM: ESTA) - **Industry**: Medical technology focused on breast aesthetics and reconstruction - **Market Presence**: Over 4.5 million devices sold in 90 countries, with a successful U.S. launch following FDA approval in late 2024 [2][6] Key Financial Highlights - **2025 Revenue Growth**: Achieved a 27% growth globally, with revenue between $210.5 million and $211.5 million [3][6] - **U.S. Market Performance**: Generated over $45 million in revenue in the first year of U.S. operations, capturing approximately 20% market share [9][6] - **Profitability**: Achieved EBITDA positive status in Q3 2025, with expectations to maintain this in Q4 and beyond [7][6] - **Cash Position**: Improved cash balance to $75.5 million at the end of 2025, a $5 million increase from Q3 2025 [7][6] Product Innovation and Market Strategy - **Unique Product Offering**: Motiva implants feature four patented technologies, including SmoothSilk, which enhances biocompatibility and reduces inflammation [4][5] - **Minimally Invasive Platform**: The launch of Preservae is expected to revolutionize the market, targeting a previously untapped segment of affluent women [11][16] - **Market Expansion**: Plans to add 15 sales representatives in 2026 to support growth in the augmentation space and prepare for the reconstruction indication [12][58] Marketing and Brand Awareness - **Marketing Success**: Achieved over 9.2 billion impressions in the first year, with notable celebrity endorsements driving brand awareness [10][11] - **Consumer Trends**: Increased openness about breast augmentation procedures, aided by social media and mainstream media coverage [20][21] Future Growth Drivers - **Reconstruction Indication**: Anticipated approval of the PMA supplement for reconstruction, which could double the addressable market in the U.S. [39][40] - **International Expansion**: Continued growth expected in Latin America, particularly in Mexico and Colombia, despite challenges in Brazil [45][46] - **APAC Market Strategy**: Plans to launch Preservae in Japan and South Korea in 2026, leveraging existing market share [47][48] Competitive Landscape - **Market Position**: Established a strong foothold in the U.S. market with minimal competitive response from larger players like J&J and Alcon [37][38] - **Sientra's Exit**: Noted that Sientra has de-emphasized its business, allowing Establishment Labs to capture market share more effectively [37][38] Financial Outlook - **Revenue Projections**: Expecting at least 25% growth in 2026 and 2027, driven by existing momentum and new product launches [23][31] - **Gross Margin Improvement**: Achieved over 70% gross margin, with expectations for further expansion as the minimally invasive platform is launched [23][56] Summary Establishment Labs is well-positioned for significant growth in the breast aesthetics and reconstruction market, driven by innovative products, effective marketing strategies, and a strong financial foundation. The company anticipates continued expansion in both domestic and international markets, with a focus on enhancing profitability and market share through strategic initiatives and product launches.

Financial Results - Establishment Labs Holdings Inc. announced preliminary unaudited financial results for the quarter and year ended December 31, 2025[5] - The independent registered public accounting firm, CBIZ, Inc., has not audited or reviewed the preliminary financial information[7] Cautionary Statements - The financial information provided is forward-looking and may differ materially from actual results, emphasizing the need for caution in reliance on these estimates[7]

Core Insights - Establishment Labs Holdings Inc. is a global medical technology company focused on enhancing women's health, particularly in breast aesthetics and reconstruction [3] - The company will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026, at 9:45 a.m. PT [1] Company Overview - Establishment Labs offers a range of solutions for breast health, aesthetics, and reconstruction in over 90 countries, having delivered over four million Motiva® devices since 2010 [3] - The company's product portfolio includes minimally invasive technologies such as Mia Femtech® for breast harmonization and Preservé® for breast augmentation and revision [3] - The Motiva Flora® tissue expander is the only regulatory-approved expander globally with an integrated port using radio-frequency technology, which is MRI conditional [3] - Establishment Labs has over 200 patent applications across 20 patent families and has published over 100 scientific and clinical studies in peer-reviewed journals [3] - The company operates two manufacturing facilities in Costa Rica that comply with ISO13485:2016 and FDA 21 CFR 820 standards [3]

Core Insights - Establishment Labs (ESTA) has submitted its Motiva breast implants to the FDA for approval in primary and revision breast reconstruction, expanding its market beyond elective procedures [1][9] - The submission is part of the company's strategy to utilize existing clinical data and early commercial traction to enter a less innovation-heavy segment of breast care, potentially leading to more stable growth [2][4] Company Developments - If approved, the reconstruction indication could significantly enhance Establishment Labs' business by tapping into a reimbursement-backed market with steadier procedure volumes compared to elective augmentation [4] - ESTA's current market capitalization stands at $2.22 billion, with projected earnings growth of 54.84% for the next year [5] - The FDA submission is supported by a 274-patient IDE study conducted across 17 U.S. sites and one in Europe, evaluating the safety and performance of Motiva implants in post-mastectomy reconstruction [10][12] Product Details - The filing includes Motiva SmoothSilk Round and Ergonomix implants, which feature patented SmoothSilk surface technology for enhanced biocompatibility and reduced inflammatory response [11] - Since gaining FDA approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., and the company has a commercial presence in reconstruction through the Motiva Flora tissue expander [12] Industry Outlook - The global breast implants market was estimated at $2.66 billion in 2024 and is projected to reach $5.16 billion by 2033, growing at a CAGR of 7.7% from 2025 to 2033, driven by rising demand for aesthetic procedures and technological advancements [13]